Saras Capital is a venture capital firm.
It has taken part in 2 funding rounds across 2 Israeli companies1,2.
Most recent: Undecimal Bio’s Seed of $18M1, announced Oct 13, 2026.
Israeli rounds
| Oct 13, 2026 | Undecimal Biobiotech, RNA therapeutics | Seed | $18M | Participant |
| Jan 13, 2026 | Converge Biobiotech, ai | Series A | $25M | Participant |
Israeli portfolio
Who invests alongside Saras Capital?
Sources
- 1CTech by Calcalist, Oct 13, 2026. “Undecimal Bio raises $18 million Seed to tackle a key obstacle in RNA medicines”
- 2CTech, Jan 13, 2026. “Converge Bio raises $25 million Series A to accelerate AI drug discovery”
Which Israeli startups has Saras Capital invested in?
Saras Capital has invested in Undecimal Bio and Converge Bio.
How many rounds has Saras Capital led?
Saras Capital has not led any of the 2 rounds it joined.
What was Saras Capital’s most recent Israeli investment?
Undecimal Bio’s Seed of $18M, announced Oct 13, 2026.